Truist raises Neurocrine Bio stock price target on strong sales By Investing.com

Neurocrine Biosciences reported Q1 2026 EPS of $1.94 versus $1.17 expected and revenue of $811 million versus $766.85 million expected, a 65.81% EPS beat and 5.76% revenue beat. Truist raised its price target to $155 from $140, citing stronger-than-expected Ingrezza and Crenessity sales and an improved base-business outlook, while Oppenheimer lifted its target to $230 from $220. The article also noted publication of CRENESSITY dosing guidelines, reinforcing the drug’s commercial and clinical profile.

Analysis

NBIX is transitioning from a single-asset sentiment story to a cleaner earnings multiple story. When a growth biopharma prints both revenue and EPS upside while the core franchise still looks durable, the market usually rerates the stock less on near-term beats and more on perceived visibility into 12-18 month cash flows; that is where the second leg of upside comes from. The key read-through is that management appears to have enough commercial traction to finance pipeline optionality without needing to dilute or de-risk aggressively.

The bigger competitive implication is that stronger execution in the core business raises the bar for peers with similar neuro/rare-disease exposure but weaker commercial momentum. If this quarter is repeatable, the market may start paying up for names with a visible bridge from marketed assets to pipeline inflection, while penalizing companies that are still pre-catalyst but burning capital. In other words, the winner is not just NBIX — it is the subset of biotech where base business can fund the next leg of growth; the losers are “story only” names with no operating leverage.

The main risk is that the move can overshoot on earnings enthusiasm before the market has evidence that the growth rate is sustainable beyond the next couple of quarters. This is still a biotech name with event risk: any soft prescription trend, reimbursement pressure, or a pipeline readout delay can compress the multiple quickly, especially if investors were pricing in a cleaner path than actually exists. The 2027 pipeline window matters more for the long-term rerate than another quarter of beats, so the stock may trade well until it doesn’t if that bridge weakens.

Consensus may be underestimating how much of the upside is now about quality of execution rather than peak pipeline optionality. The market often treats biopharma upside as binary around catalysts, but here the base business is the catalyst enabler; that usually supports a higher floor and reduces drawdown risk relative to peers. That said, if the stock approaches the upper end of sell-side targets before the next data set, upside becomes more about multiple expansion than fundamentals, which is where risk/reward worsens fast.

Key Decisions for Investors

• Long NBIX for 1-3 months into the next earnings cycle; use pullbacks toward the low-$140s as entry, with a near-term target in the mid-$150s and a tighter stop below the post-earnings support zone.
• For higher-conviction upside with defined risk, buy NBIX call spreads expiring after the next quarterly print; structure for 2:1 or better payout if the market starts pricing in a higher forward multiple.
• Pair trade: long NBIX / short a weaker mid-cap biotech with no visible self-funded growth profile over the next 12 months; the trade is a quality-vs.-speculation expression and should work if capital rotates toward cash-generative biotech.
• Trim or hedge if NBIX approaches the low-$150s before additional pipeline visibility; at that point the stock may have priced in the commercial durability story faster than fundamentals can confirm it.